|
Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
|
Free subscription to Biologic Bulletin newsletter
|
|
|
Reminders of new CME/CE activities
|
 REGISTER NOW
|
|
This Web site is supported by an
unrestricted educational grant from
Genentech, Inc.
|
|
|
|
 |
| CME/CE Programs : CME Programs : New Long-Term Efficacy Data on Biologics in Psoriasis: Impact on Patient Management |
New Long-Term Efficacy Data on Biologics in Psoriasis: Impact on Patient Management
CME Teleconference/Webcast, November/December 2006
Program Chair
Jeffrey M. Sobell, MD
Assistant Professor of Dermatology
Tufts University School of Medicine
Boston, Massachusetts
Program Faculty
David J. Cohen, MD
Assistant Professor of Medicine
Chief of Dermatology
Mercer University
Macon, Georgia
Scott A. Fretzin, MD
Clinical Assistant Professor
Indiana University School of Medicine
Indianapolis, Indiana
Lubomira Scherschun, MD
Senior Staff Dermatologist
Henry Ford Hospital
Detroit, Michigan
James E. Turner, MD, PhD
Clinical Professor, Division of Dermatology
University of Tennessee School of Medicine
Memphis, Tennessee
Jeffrey M. Weinberg, MD
Assistant Clinical Professor of Dermatology
Columbia University College of Physicians and Surgeons
New York, New York
Co-sponsored by the Dannemiller Memorial Educational Foundation and Curatio CME Institute.
Support for this activity has been made possible by an educational grant from Genentech, Inc.
Released: December 2006
Expiration Date for Credit: December 31, 2007
Target Audience
This CME activity is designed for dermatologists who treat patients with psoriasis.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Review the mechanism of action of T-cell agents and anti-TNF agents in the treatment of psoriasis
- Differentiate between the anti-TNF agents and T-cell agents
- Summarize clinical experience with long-term use of biologics for psoriasis
- Discuss practical guidelines for long-term treatment of patients with psoriasis
Accreditation
The Dannemiller Memorial Educational Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
This activity should take approximately 1 hour to complete. The participant should, in order, read the objectives and view the presentation including the question and answer session, complete the posttest, and complete the registration and evaluation forms. To access the posttest and registration and evaluation forms, click on the "CME/CE Posttest" icon at the end of the presentation. To receive credit for this activity, follow the instructions provided on the posttest. Credit is valid through December 31, 2007. No credit will be given after this date. There is no fee associated with this CME/CE activity.
Upon successful completion of this activity and posttest, a (CME) certificate for up to 1 AMA PRA Category 1 CreditTM (CME) will be issued online and the participant will be able to print the certificate at their location. No additional certificate will be mailed. The participant will have unlimited access to their personal transcript, documenting their participation and achievement.
In the event you are unable to print the certificate, please submit the posttest and then e-mail editor@dannemiller.com; a certificate will be mailed to you within 2 weeks.
Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation, Genentech, or Curatio CME Institute. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Off Label/Investigational Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Disclosure Statements
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), the
Dannemiller Memorial Educational Foundation requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. Accordingly:
David J. Cohen, MD
Speaker/Consultant/Investigator: Amgen, Abbott, Centocor, Genentech
Speaker: Novartis
Scott A. Fretzin, MD
Speaker: Amgen, Connetics, Genentech, Medicis
Consultant: Centocor, Genentech, Medicis
Investigator: Abbott, Astellas, Centocor, Genentech, 3M
Lubomira Scherschun, MD
Investigator: Abbott, Amgen, Biogen Idec, Genentech
Consultant: Amgen, Biogen Idec, Genentech
Speaker: Amgen, Genentech
Jeffrey M. Sobell, MD
Speaker/Consultant: Abbott, Amgen, Centocor, Genentech
Investigator: Abbott, Centocor, Genentech
James E. Turner, MD, PhD
Speaker/Consultant/Investigator: Genentech
Jeffrey M. Weinberg, MD
Speaker: Amgen, Genentech
Consultant: Abbott, Genentech
Investigator: Genentech
The Dannemiller staff and Helix Medical Communications staff that were involved in the development of this activity have no financial relationships with any commercial interests that are relevant to this activity.
To resolve identified conflicts of interest, the educational content was fully peer reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based and commercially balanced.
|
|
|
|
